“…The course of tumor immunotherapy has shown that Treg-targeting compounds may be good candidates for treatment based on immune system modulation. Reducing Treg activity promotes the shift of the tumor microenvironment from being strongly suppressive to the physiologically active [45,46]. Among potential methods that can achieve this effect are: IL-10 receptor blockade [47], selectin blockade [48], inhibition of chemokines responsible for Treg cells recruitment (CCL17, CCL22, CCL20 or CXCL13), blocking chemokine receptors specifically expressed by Treg effector cells (e.g.…”